Lopatriello S, Amoroso D, Donati S, Alabiso O, Forti L, Fornasiero A, Smergo A, Lalli A, Iacono C, Lucenti A, D'Alonzo L, Negrini C
PBE Consulting, Verona, Italy.
Eur J Cancer. 2008 Nov;44(17):2615-22. doi: 10.1016/j.ejca.2008.08.010. Epub 2008 Sep 18.
To describe the healthcare resource consumption of metastatic colorectal cancer (MCRC) patients in the Italian healthcare setting.
A retrospective chart analysis estimating direct medical costs of first-line infusional 5-Fluorouracil (5-FU) or oral Capecitabine (CAP), associated or not with other chemotherapies, from the Italian Healthcare Service (IHCS) and Hospital (H) perspectives.
202 subjects were analysed. CAP patients (N=66) were older, with a more compromised clinical status and received less chemotherapy agents in association than 5-FU patients (N=136). From the IHCS perspective, mean total costs per patient were 12,029 euro and 5,781 euro in the 5-FU and CAP arms respectively; 7,338 euro and 4,688 euro from the H perspective. The infusional administration route of 5-FU was a cost driver from both perspectives. Sensitivity analyses found the results to be robust to variations in base case parameters.
Management of MCRC by oral chemotherapies may be an economically advantageous option to both IHCS and hospitals.
描述意大利医疗环境下转移性结直肠癌（MCRC）患者的医疗资源消耗情况。
从意大利医疗服务机构（IHCS）和医院（H）的角度，通过回顾性病历分析评估一线输注5-氟尿嘧啶（5-FU）或口服卡培他滨（CAP）（无论是否联合其他化疗）的直接医疗费用。
分析了202名受试者。与5-FU组患者（N = 136）相比，CAP组患者（N = 66）年龄更大，临床状态更差，联合使用的化疗药物更少。从IHCS角度看，5-FU组和CAP组每位患者的平均总费用分别为12,029欧元和5,781欧元；从医院角度看分别为7,338欧元和4,688欧元。5-FU的输注给药途径在两个角度都是成本驱动因素。敏感性分析发现结果对基础病例参数的变化具有稳健性。
口服化疗药物治疗MCRC对IHCS和医院而言可能是一个经济上有利的选择。
